• e-peas

  Participated · Equity · Jul 2020

  Founded in 2014 and headquartered in Louvain-la-Neuve, e-peas develops and markets ultra-low-power semiconductor technology that enables devices to operate from ambient energy sources such as light, RF, vibration, and heat. Its product portfolio includes energy-harvesting power management ICs, microcontrollers, and sensor solutions backed by about 15 years of research and patented IP. The company says its solutions power high-volume applications including solar-powered remote controls, HVAC systems, cameras, and smart tracking devices for global customers. e-peas aims to extend battery lifespans and eliminate battery replacements for industrial and IoT device designers. Financially, the company has raised multiple rounds including €8 million in 2020, €17.5 million in March 2024, and the recent €19.2 million round to support commercial scaling and international expansion. The firm also maintains offices in Switzerland and the USA.

• A-Mansia Biotech

  Participated · Equity · Apr 2018

  A-MANSIA is a Belgian microbiome company founded in 2016 that develops health products built on the properties of the bacterium Akkermansia muciniphila. Its R&D is based on discoveries from Wageningen University and the University of Louvain, and the company controls a strong intellectual property portfolio stemming from patents developed by both universities. Preclinical studies showed daily administration of live A. muciniphila—and pasteurised A. muciniphila—improved metabolic disorders and inflammatory conditions in high-fat‑fed mice, with pasteurised bacterium exhibiting equal or greater beneficial effects. A first human exploratory study at Cliniques universitaires Saint‑Luc (Brussels) is ongoing and interim results indicate the product is safe and well tolerated. The company has identified active components isolated from A. muciniphila that can replicate beneficial properties and plans both a proprietary nutritional supplement commercial launch and a pharmaceutical discovery effort based on those components. The recent financing and grant are intended to advance these development programs.

• Promethera Biosciences

  Participated · Series B · Mar 2012

  Promethera develops cell-based therapies and complementary biologics to reduce the need for liver transplantation, with lead programs derived from its patented HepaStem platform. Its lead product candidate, HepaStem, consists of expanded liver stem cells manufactured under cGMP and is being evaluated in a phase 2a trial in ACLF with safety and efficacy results presented at EASL 2019. The company is preparing to initiate a late-stage clinical trial in NASH, planned to start in Europe and expand to the US and Asia. Promethera also advances H2Stem and antibody programs such as the anti-TNF-R1 antibody Atrosimab to diversify its pipeline. The company operates internationally with facilities in Mont-Saint-Guibert (Belgium), Durham (NC, USA), Tokyo (Japan) and Basel (Switzerland). The organization is scaling manufacturing and advancing preclinical work while progressing multiple clinical programs. Promethera Biosciences is a global innovator in cell-based medicines focused on severe liver diseases. Its lead clinical program is derived from the company’s patented HepaStem cell technology platform, which the company says has immune-modulatory and anti-fibrotic properties. In addition to cell-based therapies, Promethera develops antibody technologies to complement and diversify its therapeutic options. The company operates R&D and GMP facilities in Mont-Saint-Guibert, Belgium, and Durham, North Carolina, USA. It recently acquired Baliopharm AG, adding an antibody candidate that specifically binds TNF-R1 to its pipeline. Promethera plans to use new funding to accelerate and broaden clinical development in indications with significant unmet need, including acute-on-chronic liver failure (ACLF), NASH and fibrosis. Promethera Biosciences is a clinical-stage biopharmaceutical company focused on cell therapy and regenerative medicine for inborn and acquired liver diseases. It develops products using allogeneic progenitor cells, stem cells and mature hepatocytes harvested from non-transplantable healthy human livers (HHALPC, HHLivC) and has three cell products: HepaStem, H2Stem, and Heparesc. The pipeline targets both orphan indications (urea cycle disorders, α1‑antitrypsin deficiency, hemophilia) and larger indications such as acute-on-chronic liver failure (ACLF), fibrosis and nonalcoholic steatohepatitis (NASH). Promethera plans to expand its development focus to these larger indications and accelerate clinical development toward the clinic. Headquartered in Mont-Saint-Guibert, Belgium, Promethera was founded in 2009 as a spin-off of Université catholique de Louvain and maintains a U.S. operation with a GMP manufacturing facility in Durham, North Carolina. The company raised EUR 10 million in a Series C-extension to fund these initiatives and support expansion into Asian markets. Promethera Biosciences develops Promethera® HepaStem, a cell-based therapy for in-born errors of metabolism and acquired liver diseases, and Promethera® H2Screen and H3Screen, non-therapeutic in vitro products based on a patented liver progenitor cell type. The company was founded in 2009 as a spin-off of the Université Catholique de Louvain (UCL) and is led by CEO Eric Halioua. It is clinical-stage and intends to use recent funding to advance the clinical development of HepaStem and a collaborative program with EMD-Millipore. The platform is based on cells isolated from healthy adult human livers. Promethera has 44 employees. Promethera Biosciences develops and commercializes allogeneic progenitor-cell products to treat liver diseases and offers liver cell models for the pharmaceutical industry. Its lead products include Promethera® HepaStem, a cell therapy for severe liver diseases in children and adults, and Promethera® HepaScreen, a cell model that mimics human liver metabolism and detoxification for drug testing. The company was founded in 2009 as a spin-off of the Université Catholique de Louvain and is led by CEO Eric Halioua. Promethera is based in Mont-Saint-Guibert, Belgium and currently employs 40 people. In March 2012 it raised €23.6m in a Series B composed of a €17m capital increase and a €6.6m loan from the Walloon Region. New strategic and financial backers in the round include Boehringer Ingelheim, Shire, Mitsui Global Investment, ATMI and SambrInvest, joining earlier Series A investors.

• GreenWatt

  Participated · Equity · Mar 2012

  GreenWatt is a waste-to-energy company that designs, develops, commercializes and maintains locally integrated turn-key biogas installations for the agro-food and beverage industry. Its systems produce biogas that can be used in combined heat and power (cogeneration) or upgraded to natural gas‑quality biomethane for grid injection. Target customers include farmers, food and beverage companies, food service and food retail businesses, and other sustainable biomass users. The company was founded in 2004 as a spin-off of Université Catholique de Louvain (UCL) and is led by CEO Philippe Mengal. Headquartered in Louvain-la-Neuve, Belgium, GreenWatt sells and services on-site installations and supports clients through operation and maintenance.

No current team members are available.